Minocycline
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1971
- First approval year
- 1971
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Minocycline
- Molecular weight
- 457.48
- Structure (SMILES)
- CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
- 2 naphthacenecarboxamide 4 7 bis dimethylamino 1 4 4a 5 5a 6 11 12a octahydro 3 10 12 12a tetrahydroxy 1 11 dioxo 4s 4 alpha 4a alpha 5a alpha 12a alpha
- 2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5A.ALPHA.,12A.ALPHA.))-
- 4 7 bis dimethylamino 1 4 4a 5 5a 6 11 12a octahydro 3 10 12 12a tetrahydroxy 1 11 dioxo 2 naphthacenecarboxamide
- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
- minociclina
- Minociclina
- minocycline
- Minocycline
- MINOCYCLINE [HSDB]
- minocycline [INN]
- MINOCYCLINE [MART.]
- MINOCYCLINE [MI]
- MINOCYCLINE [USAN]
- MINOCYCLINE [VANDF]
- Minocycline [WHO-DD]
- minocycline hsdb
- minocycline inn
- minocycline mart
- minocycline mi
- minocycline usan
- minocycline vandf
- minocycline who dd
- TIGECYCLINE IMPURITY C [EP IMPURITY]
- tigecycline impurity c ep impurity
- CAS registry numbers
- 10118-90-8
- ChEMBL ID
- CHEMBL1434
- InChIKey
- DYKFCLLONBREIL-KVUCHLLUSA-N
- FDA ingredient codes (UNII)
- FYY3R43WGO
- A01AB23
- D10AF07
- J01AA08
Sources for recorded values
- 6979
- 6980
- Applicant
- TRIAX PHARMS
- Approval date
- 30 Jun 1971
- Application number
- NDA050315
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- minocycline
- Type
- Synthetic organic
- Drug name stem
- -cycline
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
Open Targets mechanisms
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Periodontitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Skin Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Memory Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001072
- Subject identifier
- D008569
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Carotid Stenosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002615
- Subject identifier
- D016893
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pneumonia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Child Development Disorders, Pervasive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003756
- Subject identifier
- D002659
- Condition
- Autistic Disorder
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003758
- Subject identifier
- D001321
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003761
- Subject identifier
- D003865
- Condition
- Inflammatory Bowel Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003767
- Subject identifier
- D015212
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003890
- Subject identifier
- D019966
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
And 48 more, listed on the interactive page.
- Condition identifier
- EFO_0000401
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000649
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000701
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000712
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0001072
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002615
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0003756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003758
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003767
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003890
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004240
- Highest recorded phase
- 3
And 110 more, listed on the interactive page.
- Event
- abdominal distension
- Reports
- 43
- Reporting signal score
- 31.8735
- Event
- acute febrile neutrophilic dermatosis
- Reports
- 15
- Reporting signal score
- 38.0345
- Event
- anti-neutrophil cytoplasmic antibody positive vasculitis
- Reports
- 21
- Reporting signal score
- 63.5055
- Event
- antineutrophil cytoplasmic antibody positive
- Reports
- 8
- Reporting signal score
- 27.2678
- Event
- antinuclear antibody positive
- Reports
- 15
- Reporting signal score
- 30.3393
- Event
- apparent death
- Reports
- 27
- Reporting signal score
- 90.1804
- Event
- application site discolouration
- Reports
- 11
- Reporting signal score
- 31.7842
- Event
- arteritis
- Reports
- 10
- Reporting signal score
- 35.6599
- Event
- arthralgia
- Reports
- 123
- Reporting signal score
- 49.0199
- Event
- arthritis
- Reports
- 82
- Reporting signal score
- 120.965
- Event
- autoimmune hepatitis
- Reports
- 53
- Reporting signal score
- 144.952
- Event
- benign intracranial hypertension
- Reports
- 11
- Reporting signal score
- 28.7674
- Event
- bone erosion
- Reports
- 73
- Reporting signal score
- 299.838
- Event
- bone hyperpigmentation
- Reports
- 46
- Reporting signal score
- 298.115
- Event
- c-reactive protein abnormal
- Reports
- 27
- Reporting signal score
- 67.7579
- Event
- c-reactive protein increased
- Reports
- 46
- Reporting signal score
- 53.4105
- Event
- chronic hepatitis
- Reports
- 11
- Reporting signal score
- 34.6812
- Event
- conjunctival pigmentation
- Reports
- 12
- Reporting signal score
- 73.594
- Event
- diverticulitis
- Reports
- 28
- Reporting signal score
- 31.1786
- Event
- drug hypersensitivity
- Reports
- 134
- Reporting signal score
- 77.5986
- Event
- drug intolerance
- Reports
- 187
- Reporting signal score
- 302.929
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 139
- Reporting signal score
- 320.768
- Event
- drug-induced liver injury
- Reports
- 95
- Reporting signal score
- 190.648
- Event
- dyspepsia
- Reports
- 44
- Reporting signal score
- 36.8739
- Event
- eosinophilia
- Reports
- 28
- Reporting signal score
- 33.7785
And 55 more, listed on the interactive page.
- NCT00029874
- NCT00277355
- NCT00047723
- NCT00355576
- NCT00063193
- NCT00145106
- NCT00240513
- NCT00392223
- NCT00988026
- NCT01206348
- NCT01362010
- NCT02250859
- NCT02695446
- NCT02815267
- NCT02815280
- NCT02815332
- NCT02946788
- NCT00154895
- NCT00203112
- NCT00666887
- NCT04291456
- NCT00203697
- NCT00361257
- NCT00371332
- NCT00662532
And 92 more, listed on the interactive page.
- Dose
- Approx. 1 mg/kg
- Route
- Oral
- How often
- Once daily
- Food may reduce esophageal irritation
- May be taken with or without food
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 5
- Polar surface area
- 164.63
- Calculated partition coefficient (ALogP)
- 0.19
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 33
- Molecular formula
- C23H27N3O7
- Natural product
- Yes
Oral bioavailability
- Median
- 98.75
- Mean
- 98.75
- Minimum
- 97.5
- Maximum
- 100
- Unit
- %
- Assays
- 2
- Standard deviation
- 1.76777
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (197)
- A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
- A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
- A Pharmacokinetic Study of Minocycline in Male and Female Volunteers
- A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer
- A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema
- A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
- A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients
- A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- A Proof-of-Concept Study of Minocycline in Autism
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
- A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
- A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
- A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
- A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy
- A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
- A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
Approved for (2)
In development for (63)
- Age-related macular degeneration Phase 2
- Alcohol dependence Phase 1
- Amyotrophic lateral sclerosis Phase 3
- Angelman syndrome Phase 2
- Asthma Phase 2
- Atrial fibrillation Phase 2
- Autism Phase 1
- Autism spectrum disorder Phase 1
- Autoimmune encephalitis Phase 2
- Bipolar disorder Phase 3
- Brain injury Phase 1
- Cerebral amyloid angiopathy Phase 1
- Colorectal cancer Phase 2
- Cystic fibrosis Phase 2
- Cystoid macular edema Phase 1
- Depressive disorder Phase 3
- Drug dependence Phase 3
- Esophageal cancer Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Fibromyalgia Phase 1